All these data suggest that AZ32 could inhibit the transporter activity of ABCG2 to reverse ABCG2-mediated multidrug resistance in colorectal cancer by competing with the substrate chemotherapeutic drugs to bind ABCG2. This evidence concerns the gene ABCG2 and colorectal cancer.